Altre lingue Alzinova AB

Azioni

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 18:00:00 28/06/2024			Variaz. 5gg	Var. 1 gen.
1,21 ^SEK	+3,42%		+2,54%	-60,13%

18/06	Alzinova AB (Publ) annuncia che tutti i pazienti sono stati reclutati nella parte ad alto dosaggio dello studio di fase 1B di Alzinova	CI
10/06	Alzinova AB (publ) annuncia una nuova revisione esterna della sicurezza per lo studio di fase 1b	CI

Alzinova’s rights issue oversubscribed	25/06
Alzinova announces change of Certified Adviser and Liquidity Provider	24/06
Alzinova presents at the prestigious AAIC Alzheimer's Conference	19/06
All patients have been recruited in the high-dose part of Alzinova's phase 1b study	18/06
Alzinova AB Announces All Patients Have Been Recruited in the High-Dose Part of Alzinova's Phase 1B Study	18/06
The last day of trading in subscription rights in Alzinova’s rights issue	17/06
New positive safety review for Alzinova's phase 1b study	10/06
Alzinova AB Announces New External Safety Review for Phase 1b Study	10/06
The subscription period in Alzinovas rights issue of shares starts today	05/06
Alzinova publishes prospectus in connection with rights issue of shares	03/06
Bulletin from the annual general meeting of Alzinova AB (publ)	29/05
IRLAB appoints Kristina Torfgard as new CEO	28/05
Alzinova publishes interim report January – March 2024	28/05
Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2024	28/05
Sweden’s IRLAB Therapeutics Names New CEO	27/05
IRLAB appoints Kristina Torfgård as new CEO	27/05
Alzinova: First patient dosed with a higher dose of ALZ-101 in the phase 1b study	21/05
Alzinova AB Announces the First Patient Dosed with A Higher Dose in the Company's Phase 1B Study (Part A2) with the Vaccine Candidate ALZ-101	21/05
Alzinova participates in several conferences and investor meetings in the spring of 2024	13/05
Alzinova publishes the Annual Report for 2023	07/05

Non ci sono risultati per questa ricerca